Exhibit 124 · Randomized trial report
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial
Twenty-one percent of AZT recipients and 4 percent of placebo recipients required multiple red-cell transfusions (P less than 0.001).
The companion toxicity report to the pivotal AZT trial, published in the same issue. Multiple red-cell transfusions were needed by 21% of AZT recipients and 4% of placebo recipients; hemoglobin fell below 7.5 g/dL in 24% and 4%; neutropenia occurred in 16% and 2%.
- Source
- Douglas D. Richman et al., New England Journal of Medicine 317(4):192–197
- Date
- 23 July 1987
- Quoted from
- Abstract (N Engl J Med 1987;317:192-7)
- Grade
- Peer-reviewed
- Document
- https://doi.org/10.1056/NEJM198707233170402
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit